Navigation Links
Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardium's New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
Date:7/26/2012

artnering and other economic monetizations.  Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium® Health Sciences healthy lifestyle product platform.  The Company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that enhancements in the uptake of adenovectors can be successfully applied to improve the uptake, applicability or therapeutic effects of Generx in human patients; that Generx can be successfully advanced in clinical studies outside of the U.S.; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successfu
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
2. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
3. First targeted and programmable nanomedicine to show clinical antitumor effects published
4. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
5. Edarbyclor (azilsartan medoxomil and chlorthalidone) Head-to-Head Data Published in Hypertension
6. Spiral Flow(TM) Grafts Enhance Patient Outcomes - New Paper Published in the Prestigious Annals of Vascular Surgery
7. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
8. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
11. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Shire plc (LSE: SHP, ... Mathew to its Board of Directors as a Non-Executive ... Compliance & Risk Committee of the Shire Board. Both appointments ... Sara previously served as Chairman, President and Chief Executive Officer ... During her 12-year tenure at D&B, she helped drive the ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has ... Africa Biomedical Sensors Market - Growth, Trends & Forecasts ... The Middle East & Africa ... 2018 at a CAGR of 3.26% over the period ... sensors that are adaptable to the genetic formulation of ...
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug discovery ... ) today confirmed its comprehensive scientific review has ... platforms in areas of unmet patient need. Novogen ... remaining preclinical projects prior to entering into Phase ... Acting Chief Executive Officer, Iain ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... Health , Inc. (Nasdaq: GHDX ) today announced that ... November 8 at 4:30 p.m. Eastern Time to discuss its third ... release of the third quarter financial results after market close. ... access the live conference call on November 8 at 4:30 p.m. ...
... Verenium Corporation (Nasdaq: VRNM ), a ... solutions, today announced that it has renewed and extended ... global provider of heat transfer, separation and fluid handling ... Laval signed an agreement to jointly market enzymatic degumming ...
... the physiocrine therapeutics company, today announced a $23 ... Associates.  Domain joins existing venture investors Alta Partners, ... in the financing.  Proceeds will be used to ... advance physiocrine drug candidates into clinical trials.  Physiocrines ...
Cached Biology Technology:Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... the RIKEN SPring-8 Center in Harima, Japan have clarified ... (qNOR), a bacterial enzyme that offers clues on the ... their importance to fundamental science, the findings provide key ... and greenhouse gas hundreds of times more potent than ...
... 2012 /PRNewswire-iReach/ -- Global Information Inc. (GII) is ... in Medical Applications: The Global Market " by BCC ... The global nanomedicine market reached $63.8 billion ... expected to grow to $130.9 billion by 2016 at a ...
... ethanol, the type of alcohol found in alcoholic beverages, can ... known as Caenorhabditis elegans , which is used frequently ... scientists said they find their discovery difficult to explain. ... Steven Clarke, a UCLA professor of chemistry and biochemistry and ...
Cached Biology News:New study sheds light on evolutionary origin of oxygen-based cellular respiration 2Nanotechnology in Medical Applications: The Global Market 2Nanotechnology in Medical Applications: The Global Market 3Tiny amounts of alcohol dramatically extend a worm's life, but why? 2Tiny amounts of alcohol dramatically extend a worm's life, but why? 3Tiny amounts of alcohol dramatically extend a worm's life, but why? 4